Common name
|
B-hROR1 CT26.WT
|
Catalog number
|
322263
|
|
Aliases
|
NTRKR1, dJ537F10.1
|
Disease
|
Colon carcinoma
|
Organism
|
Mouse
|
Strain
|
BALB/c
|
|
Tissue types
|
Colon
|
Tissue
|
Colon
|
Description
The mouse
Ror1 gene was replaced by human
ROR1 coding sequence in B-hROR1 CT26.WT cells. Human ROR1 is highly expressed on the surface of B-hROR1 CT26.WT cells.
Application
B-hROR1 CT26.WT cells have the capability to establish tumors
in vivo and can be used for efficacy studies.
Targeting strategy
Gene targeting strategy for B-hROR1 CT26.WT cells. The exogenous promoter and human ROR1 coding sequence was inserted to replace part of murine exon 3 and all of exon 4. The insertion disrupts the endogenous murine Ror1 gene, resulting in a non-functional transcript.
Protein expression analysis
ROR1 expression analysis in B-hROR1 CT26.WT cells by flow cytometry. Single cell suspensions from wild-type CT26.WT and B-hROR1 CT26.WT cultures were stained with species-specific anti-ROR1 antibody. Human ROR1 was detected on the surface of B-hROR1 CT26.WT cells but not wild-type CT26.WT cells.
Tumor growth curve & body weight changes
Subcutaneous tumor growth of B-hROR1 CT26.WT. B-hROR1 CT26.WT (1×105) and wild-type CT26.WT cells (1×105) were subcutaneously implanted into BALB/c mice (female, 7-week-old, n=6). Tumor volume and body weight were measured three times a week. (A) Average tumor volume. (B) Body weight. Volume was expressed in mm3 using the formula: V=0.5 × long diameter × short diameter2. Results indicate that B-hROR1 CT26.WT cells were able to establish tumors in vivo and can be used for efficacy studies. Values are expressed as mean ± SEM.
Protein expression analysis of tumor tissue
ROR1 expression evaluated on B-hROR1 CT26.WT tumor cells by flow cytometry. B-hROR1 CT26.WT cells were subcutaneously transplanted into BALB/c mice (n=6). Upon conclusion of the experiment, tumor cells were harvested and assessed for human ROR1 expression by flow cytometry (Biolegend, 357804). As shown, human ROR1 was highly expressed on the surface of tumor cells. Therefore, B-hROR1 CT26.WT cells can be used for in vivo efficacy studies evaluating novel ROR1 therapeutics.
